Fredag 29 November | 17:47:13 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-21 08:30 Bokslutskommuniké 2024
2024-08-02 - Kvartalsrapport 2024-Q2
2024-07-29 - Extra Bolagsstämma 2024
2024-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2024-05-24 - Årsstämma
2024-02-19 - Bokslutskommuniké 2023
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-29 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2023-05-26 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-23 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 - Årsstämma
2022-05-06 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-02-18 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 - Årsstämma
2021-02-19 - Bokslutskommuniké 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-18 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 - Årsstämma
2020-02-14 - Bokslutskommuniké 2019
2019-10-18 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-08-19 - Kvartalsrapport 2018-Q2
2018-05-21 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 - Årsstämma
2018-02-19 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies är verksamt inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.
2024-05-17 11:30:00

Effective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.

Lone Carlbom Assumes Role as CEO of Bio-Works
Effective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.
In line with the CEO transition, Bio-Works’ management team is intended to be reorganized with the following positions:

  • Arne Hauge, CFO and Head of Support Functions
  • Maria Åberg, Head of Production
  • Silvia Hellström, Head of Quality Assurance
  • Lone Carlbom will continue to oversee Product Management and R & D
  • A new Head of Sales will join the management team shortly.

“Under Jonathan Royce’s leadership, Bio-Works has seen significant development and initiatives. However, we have not achieved the results that both he and the Board anticipated”, said Peter Ehrenheim, Chairman of the Board at Bio-Works. “We agree that new leadership and a strategic reset are necessary to move Bio-Works forward and realize the potential of our technology platform. Initially, Lone Carlbom will focus entirely on the company’s operations. The Board will take a more active role in implementing the company’s commercial strategy and its communications with the financial markets.”
“The Board would like to thank Jonathan Royce for his efforts and dedication during his tenure with us. Despite the challenges we faced, he has worked strenuously to lead Bio-Works, and we appreciate his contributions. We are confident that Lone Carlbom has the experience and skills required to lead Bio-Works towards a stronger and more successful future”, Ehrenheim concluded.
----------------------
Lone Carlbom brings over 25 years of experience in leadership roles within the Life Sciences and Biotech industries, with expertise in product management, technical support, and sales. Previously, she held the position of Head of Chromatography Resines and BioProcess Equipment at GE Healthcare Life Sciences (now Cytiva). Additionally, she has served as a consultant in change management and organizational development.